These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23453477)

  • 41. Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?
    Caporali R; Codullo V; Cipriani P; Giacomelli R
    Rheumatology (Oxford); 2018 Oct; 57(57 Suppl 7):vii1-vii4. PubMed ID: 30289536
    [No Abstract]   [Full Text] [Related]  

  • 42. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure.
    Solau-Gervais E; Prudhomme C; Philippe P; Duhamel A; Dupont-Créteur C; Legrand JL; Houvenagel E; Flipo RM
    Joint Bone Spine; 2012 May; 79(3):281-4. PubMed ID: 21724444
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes.
    Barra L; Bykerk V; Pope JE; Haraoui BP; Hitchon CA; Thorne JC; Keystone EC; Boire G;
    J Rheumatol; 2013 Aug; 40(8):1259-67. PubMed ID: 23378461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 45. Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period.
    Conti F; Scrivo R; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Clin Exp Rheumatol; 2009; 27(3):540-1. PubMed ID: 19604456
    [No Abstract]   [Full Text] [Related]  

  • 46. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
    Stuhlmüller B; Häupl T; Hernandez MM; Grützkau A; Kuban RJ; Tandon N; Voss JW; Salfeld J; Kinne RW; Burmester GR
    Clin Pharmacol Ther; 2010 Mar; 87(3):311-21. PubMed ID: 20032971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Should we use poor prognosis factors to start early treatment in patients with rheumatoid arthritis?
    Valor L; de la Torre Ortega I
    Reumatol Clin; 2012; 8(4):163-7. PubMed ID: 22317850
    [No Abstract]   [Full Text] [Related]  

  • 50. Radiographic progression in rheumatoid arthritis: does it still happen and does it matter?
    Bykerk VP
    J Rheumatol; 2014 Dec; 41(12):2337-9. PubMed ID: 25452176
    [No Abstract]   [Full Text] [Related]  

  • 51. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Ichinose K; Kamachi M; Yamasaki S; Nakamura H; Origuchi T; Ida H; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 53. Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α.
    Onishi S; Yoshio T; Nagashima T; Minota S
    Mod Rheumatol; 2010 Oct; 20(5):528-30. PubMed ID: 20458607
    [No Abstract]   [Full Text] [Related]  

  • 54. Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today.
    Hagenow A; Seifert J; Zeissig A; Conrad K; Kleymann A; Aringer M
    Clin Exp Rheumatol; 2013; 31(2):213-8. PubMed ID: 23295192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?
    Mulleman D; Ducourau E; Paintaud G; Ternant D; Watier H; Goupille P
    Joint Bone Spine; 2012 Mar; 79(2):109-12. PubMed ID: 22356754
    [No Abstract]   [Full Text] [Related]  

  • 56. TNF-alpha antagonists and other recombinant proteins for the treatment of rheumatoid arthritis.
    Brasington R
    J Hand Surg Am; 2009 Feb; 34(2):349-50. PubMed ID: 19135810
    [No Abstract]   [Full Text] [Related]  

  • 57. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
    Oswald M; Curran ME; Lamberth SL; Townsend RM; Hamilton JD; Chernoff DN; Carulli J; Townsend MJ; Weinblatt ME; Kern M; Pond CM; Lee A; Gregersen PK
    Arthritis Rheumatol; 2015 Feb; 67(2):344-51. PubMed ID: 25371395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.
    Nguyen DX; Cotton A; Attipoe L; Ciurtin C; Doré CJ; Ehrenstein MR
    J Allergy Clin Immunol; 2018 Sep; 142(3):978-980.e9. PubMed ID: 29935955
    [No Abstract]   [Full Text] [Related]  

  • 59. What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
    Bobbio-Pallavicini F; Caporali R; Bugatti S; Montecucco C
    J Rheumatol; 2008 Oct; 35(10):1903-5. PubMed ID: 18843754
    [No Abstract]   [Full Text] [Related]  

  • 60. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.